Sjogren’s Syndrome – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of SS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.

Clarivate Epidemiology’s SS forecast will answer the following questions:

• Of all people diagnosed with SS, how many in each country in the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 15 SS patient populations, as follows:

• Diagnosed prevalent cases of SS.
• Diagnosed prevalent cases of primary SS.
• Diagnosed prevalent cases of secondary SS.
• Diagnosed incident cases of SS.
• Diagnosed incident cases of primary SS.
• Diagnosed incident cases of secondary SS.
• Diagnosed prevalent cases of primary SS with lymphoma.
• Diagnosed prevalent cases of primary SS without lymphoma.
• Diagnosed prevalent cases of primary SS with fibromyalgia.
• Diagnosed prevalent cases of primary SS without fibromyalgia.
• Diagnosed prevalent cases of secondary SS with systemic lupus erythematosus (SLE).
• Diagnosed prevalent cases of secondary SS with rheumatoid arthritis (RA).
• Diagnosed prevalent cases of secondary SS with other autoimmune diseases.
• Diagnosed drug-treated prevalent cases of SS.
• Diagnosed non-drug-treated prevalent cases of SS.

Note: Coverage may vary by country.